Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

67.72 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage... 
Via MarketMinute
Topics Death
Earnings Scheduled For November 4, 2025
 
Via Benzinga
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup
PTC Therapeutics (PTCT) shows strong growth with 96% revenue surge and a bullish technical breakout pattern, making it a compelling biotech stock. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity
PTC Therapeutics offers strong growth and attractive valuation metrics, making it a compelling affordable growth stock for investors seeking biotech opportunities. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing
PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment. 
Via Chartmill
Earnings Scheduled For August 7, 2025
 
Via Benzinga
PTC Therapeutics Earnings Preview
 
Via Benzinga
PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup
PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech
PTC Therapeutics (PTCT) offers strong growth & attractive valuation. With revenue up 96% and a low P/E of 10.29, it's a top affordable growth stock pick in biotech. 
Via Chartmill
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
Here's Why Shares in PTC Therapeutics Soared This Week
An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful. 
Via The Motley Fool
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid. 
Via Benzinga
PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock
Discover PTC Therapeutics (PTCT), an affordable growth stock with strong revenue & EPS growth, low P/E ratio, and solid profit margins in the biotech sector. 
Via Chartmill
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided
Via Stocktwits
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another controlled trial. 
Via Benzinga
PTCT Earnings Beat but Sales Drop 4%
Via The Motley Fool
Topics Earnings
PTC THERAPEUTICS INC (NASDAQ:PTCT) Reports Q2 2025 Earnings Beat with Narrowed Loss and Strong Sephience™ Launch
PTC Therapeutics (PTCT) reported strong Q2 2025 earnings, beating revenue estimates at $179M and narrowing EPS loss. Growth driven by Sephience™ launch for PKU in U.S. & Europe. Stock up 5.4% in a... 
Via Chartmill
Topics Earnings
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact. 
Via Benzinga
These Analysts Increase Their Forecasts On PTC Therapeutics
 
Via Benzinga
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened
The regulator approved Sephience for a broad range of PKU patients, including children as young as one month, based on Phase 3 data showing sustained reductions in phenylalanine levels. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock at a Fair Valuation
PTC Therapeutics (PTCT) offers strong growth potential with solid financials and attractive valuation, making it a top pick for investors seeking affordable growth in biopharma. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS INC (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, supported by solid financial health and profitability metrics. A biotech stock worth watching. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential
PTC THERAPEUTICS INC (NASDAQ:PTCT) shows strong growth fundamentals and a promising technical breakout pattern, making it a stock to watch for growth investors. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential at a reasonable valuation, with solid profitability and financial health. A closer look at this biotech stock may be worthwhile for growth... 
Via Chartmill
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, solid profitability, and financial health, making it an interesting stock for growth investors. 
Via Chartmill
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
 
Via Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.